Report of Foreign Issuer (6-k)
February 16 2018 - 1:45PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending
16 February
2018
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline plc (the '
Company
')
Conditional Share Awards
This
notification sets out the vesting details of awards over Ordinary
Shares and American Depositary Shares ('ADS') made in 2015 under
the GlaxoSmithKline Performance Share Plan ('PSP'), which were
subject to relevant business performance conditions. The
three-year performance period for the 2015 awards commenced on 1
January 2015 and ended on 31 December 2017.
The
performance measure vesting details for those Persons Discharging
Managerial Responsibilities ('PDMRs') who received awards in 2015
are set out in the following table.
|
Outcome
and Vesting Level
|
Portion
of the Award
|
Measure
and Outcome
|
% of
maximum
|
% of
award
|
1/3
rd
|
Adjusted Free Cash Flow
- For the three-year period, the
Company achieved Adjusted Free Cash Flow calculated in accordance
with the principles for the measure of £12.47bn which is above
the threshold level of £11.48bn.
|
63
|
21
|
1/3
rd
|
Total Shareholder Return
- For the three years ending 31
December 2017, the Company's Total Shareholder Return ranked
5
th
, which
is above the threshold vesting level against a comparator group of
10 global pharmaceutical companies including GSK.
|
44
|
14.67
|
1/3
rd
|
R&D New Products
- For the three-year period, the
Company achieved New Product sales calculated in accordance with
the principles for the measure of £11.266bn, which is above
the maximum vesting level of £7.912bn (the threshold level was
£6.474bn).
|
100
|
33.33
|
|
Total vesting for 2015 award
Lapsed
|
69%
31%
|
The
notifications that follow are for awards made to PDMRs and detail
the PSP conditional awards that vested, including dividends
accrued, on 15 February 2018. The balance of the award made
to each PDMR has lapsed.
The
closing share prices of an Ordinary Share and of an ADS of
GlaxoSmithKline plc at the point of vesting on 15 February 2018
were £13.004 and $37.31.
Transaction notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Ms E Walmsley
|
b)
|
Position/status
|
Chief Executive Officer
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2015
under the Company's 2009 Performance Share Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£0.00
|
91,430
|
£0.00
|
47,391
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
138,821
£0.00
|
e)
|
Date
of the transaction
|
2018-02-15
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr R Connor
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2015
under the Company's 2009 Performance Share Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£0.00
|
71,160
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2018-02-15
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr L Debruyne
|
b)
|
Position/status
|
President, Global Vaccines
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2015
under the Company's 2009 Performance Share Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£0.00
|
18,203
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2018-02-15
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr S Dingemans
|
b)
|
Position/status
|
Chief Financial Officer
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2015
under the Company's 2009 Performance Share Plan. These shares
are subject to a two-year holding period to end in
2020.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£0.00
|
154,763
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2018-02-15
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr N Hirons
|
b)
|
Position/status
|
SVP, Global Ethics and Compliance
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
The
number of Ordinary Shares vesting on awards granted in 2015 under
the Company's 2009 Performance Share Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£0.00
|
34,502
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2018-02-15
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr B McNamara
|
b)
|
Position/status
|
CEO, GSK Consumer Healthcare
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
GlaxoSmithKline plc American Depositary Shares
('ADSs')
ISIN:
US37733W1053
|
b)
|
Nature
of the transaction
|
The number of ADSs vesting on awards granted in 2015 under the
Company's 2009 Performance Share Plan and which were made to
compensate for the value of awards forfeited on completion of the
Joint Venture with Novartis.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
$0.00
|
24,345
|
$0.00
|
4,871
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
29,216
$0.00
|
e)
|
Date
of the transaction
|
2018-02-15
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr D Redfern
|
b)
|
Position/status
|
Chief Strategy Officer
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2015
under the Company's 2009 Performance Share Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£0.00
|
56,605
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2018-02-15
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Ms C Thomas
|
b)
|
Position/status
|
SVP, Human Resources
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2015
under the Company's 2009 Performance Share Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£0.00
|
75,473
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2018-02-15
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr P Thomson
|
b)
|
Position/status
|
President, Global Affairs
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2015
under the Company's 2009 Performance Share Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£0.00
|
43,667
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2018-02-15
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr D Troy
|
b)
|
Position/status
|
SVP & General Counsel
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
GlaxoSmithKline plc American Depositary Shares
('ADSs')
ISIN:
US37733W1053
|
b)
|
Nature
of the transaction
|
The number of ADSs vesting on awards granted in 2015 under the
Company's 2009 Performance Share Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
$0.00
|
66,334
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2018-02-15
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dr P Vallance
|
b)
|
Position/status
|
Outgoing President, R&D
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2015
under the Company's 2009 Performance Share Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£0.00
|
156,984
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2018-02-15
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mrs V Whyte
|
b)
|
Position/status
|
Company Secretary
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each 'Ordinary Shares'
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2015
under the Company's 2009 Performance Share Plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£0.00
|
9,667
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2018-02-15
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: February
16, 2018
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024